Ibrutinib-Based Regimen Recommended as New Standard for Younger Mantle Cell Lymphoma Patients

A recent analysis of the TRIANGLE phase 3 clinical trial, published in The Lancet, provides critical insights into the optimal first-line treatment for patients aged 18–65 with mantle cell lymphoma. Following a 55-month follow-up period, the study evaluated three treatment arms to determine the efficacy of adding autologous stem-cell transplantation (ASCT) to ibrutinib-containing regimens. The results demonstrated that both groups receiving ibrutinib achieved significant improvements in failure-free survival and overall survival compared to standard therapies. However, the addition of ASCT to the ibrutinib regimen offered no supplementary clinical benefit and was associated with increased toxicity. Consequently, researchers conclude that induction treatment combining ibrutinib with R-CHOP plus R-DHAP (or R-DHAOx), followed by two years of ibrutinib maintenance, should be established as the new standard of care for younger patients. This finding marks a pivotal shift in therapeutic protocols, prioritizing effective pharmacological intervention over high-toxicity transplant procedures for this specific demographic, potentially improving quality of life while maintaining superior survival outcomes.